Pharmacy Quality Solutions (PQS) by Innovaccer Launches EQUIPP Copilot™, Industry-First Zero-Click Intelligent Platform to Empower Pharmacies in Value-Based, Collaborative Care
SAN FRANCISCO--(BUSINESS WIRE)--Pharmacy Quality Solutions (PQS), an Innovaccer company and leader in pharmacy-payer performance technology, today announced the launch of EQUIPP Copilot ™, the industry's first workflow-integrated intelligence platform designed to help pharmacies expand clinical services, boost productivity, and connect seamlessly with the broader healthcare ecosystem. By embedding real-time insights and automation directly into daily pharmacy operations, EQUIPP Copilot ™ redefines how pharmacists engage in value-based care, care coordination, and patient outcomes, without disrupting their workflow.
The announcement was made at the Pharmacy Quality Alliance Annual Meeting where EQUIPP Copilot ™ was introduced as the industry's first AI-enabled real-time digital copilot designed to help pharmacies participate in value-based care (VBC) and enhance operational efficiency.
'Community pharmacies are on the front lines of the value-based care evolution,' said Todd Sega, Managing Director, Pharmacy, Innovaccer. 'They face mounting pressures in the core, historical business model of dispensing medications, while needing to diversify and focus on value and patient care services in a changing payer and provider landscape. EQUIPP Copilot ™ meets this moment by delivering exactly what pharmacists need: real-time guidance and automation woven into their day-to-day workflow. It's like having a digital assistant in the pharmacy system, surfacing actionable insights and automating tasks so teams can spend more time on patients and growing revenue through clinical services.'
Pharmacies are increasingly expected to support clinical initiatives and participate in value-based care programs, but often lack the tools to do so efficiently. EQUIPP Copilot ™ solves this by embedding actionable intelligence and automation directly into their workflow, streamlining tasks, eliminating administrative burden, and enhancing patient outcomes.
Unlike standalone apps or portals, EQUIPP Copilot ™ overlays Pharmacy Management Systems (PMSs), using smart pop-ups, embedded alerts, and intelligent task automation to guide pharmacists through quality interventions at the point of care.
The key innovations of EQUIPP Copilot ™ include:
Deep Workflow Integration: Runs unobtrusively in the background, surfacing real-time patient-specific insights when clinical opportunities arise.
Real-Time Clinical Insights: Automated prompts for immunizations, care gap closures (e.g., A1C checks, Blood Pressure screenings), adherence support, and value-based opportunities.
Administrative Automation: Supports prior authorizations, medication synchronization, and patient outreach via text or call, all within this singular interface.
Customizable Dashboards: Tailored alerts and task prioritization based on pharmacy goals and payer requirements.
Agentic Task Support: Built-in agents perform repetitive tasks, allowing pharmacists to focus on high-impact care.
'Pharmacies are one of the most underutilized assets in value-based care,' said Abhinav Shashank, CEO of Innovaccer. 'By embedding intelligence and automation directly into their daily workflow, EQUIPP Copilot ™ turns every pharmacy into a proactive care hub. This is a key step toward a more connected, collaborative healthcare system, one where data drives smarter decisions and better outcomes at every touchpoint.'
The launch of EQUIPP Copilot ™ arrives as pharmacies face growing pressure to expand their clinical roles amid staffing constraints, shifting incentives, and the decentralization of care. The solution is purpose-built to support independent pharmacies, chains and health plans seeking scalable, real-time engagement tools.
EQUIPP Copilot ™ pre-registrations are open now with general availability in Q3 2025. The platform is offered to existing customers via a flexible freemium model, with advanced capabilities available à la carte to fit pharmacies of all sizes and needs.
About PQS by Innovaccer
PQS by Innovaccer aligns healthcare payers and pharmacies to achieve their shared goals of better patient outcomes and healthcare quality performance. As a neutral, trusted intermediary supporting the evolution of value-based care, PQS facilitates nationwide pharmacy-based care through our partners and the EQUIPP ® platform. Utilizing deep clinical pharmacy knowledge and over a decade of performance management experience, we help clients develop strategies, implement quality improvement programs, and optimize the quality of healthcare for their populations served. For more information on how PQS can support you, please visit www.pharmacyquality.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
After a Sharp Rally, Okta Stock Pulls Back on Cautious Outlook -- Time to Buy the Dip?
Okta turned in solid fiscal Q1 results, but conservative guidance sank the stock. The company continues to innovate, while its new go-to-market strategy is showing signs of promise. The stock is reasonably valued at current levels. 10 stocks we like better than Okta › Okta (NASDAQ: OKTA) has been in rally mode for much of this year, but the stock hit a speed bump when it reported its fiscal 2026 first-quarter results. Despite a 15% drop in its share price since May 27, the stock is still up 35% year to date, as of this writing. Let's take a closer look at the cybersecurity company's most recent results and guidance to see it if can regain its momentum. In what has been a pretty common theme of late, Okta shares fell after management issued cautious guidance. With continued uncertainty around tariffs and their effect on the economy, many companies have opted to take a conservative view when it comes to their forecasts. Okta said it saw no effect in Q1 from the macro environment, but it still thought it was prudent to stay conservative. As such, it maintained its full-year revenue forecast, calling for fiscal 2026 revenue of $2.85 billion to $2.86 billion, representing 9% to 10% growth. However, it did increase its adjusted earnings per share (EPS) outlook from a range of $3.15 to $3.20 to a new range of $3.23 to $3.28. Management called out the strong demand for newer products, like Identity Governance, Privileged Access, and Identity Threat Protection powered by Okta AI. The company is also taking steps to address rising security risks related to AI agents and other non-human identities (NHIs). To do that, it's combining its Identity Security Posture Management tools with Privileged Access to offer a unified platform that can secure both human users and NIHs across an organization. At the same time, Okta is confident its strategy of making sales teams more specialized will pay off over the long run. That confidence is backed by early results from parts of the business where this approach is already in place. For example, Okta shifted its U.S. small and mid-sized business (SMB) team to a "hunter-farmer" model last year where some reps focus on landing new customers while others focus on growing existing accounts. That team performed well in Q1, showing that this kind of focus can lead to better results over time. This all led to a solid fiscal Q1, which ended April 30. Okta's revenue increased 12% year over year to $688 million. This easily topped its prior forecast for revenue of $678 million to $680 million. Subscription revenue also increased 12% to $673 million. Adjusted EPS jumped 24% year over year to $0.86, well above the $0.76 to $0.77 outlook. Okta's net dollar retention rate -- which measures the amount of revenue spent from existing customers over the past 12 months after churn -- was 106%. Any number over 100% indicates growth. However, the metric continues to drift lower, down from 111% a year ago and 117% two years ago. Customers with annual contract values (ACVs) above $100,000 rose 7% to 4,870, and customers with ACVs of more than $1 million jumped 20% year over year. Okta's remaining performance obligation (RPO) backlog increased 21% to $4.08 billion, while its current RPO (cRPO) backlog, the subscription backlog expected to be recognized over the next 12 months, rose 14% to nearly $2.23 billion. Both metrics are based on signed contracts and are an indication of future revenue. For fiscal Q2, management guided for approximately 10% revenue growth to $710 million to $712 million. Adjusted EPS should land between $0.83 and $0.84. While Okta decided to take a cautious approach to guidance, the company is seeing growing market opportunities in a world that's only becoming more complex due to AI. While this technology is helping cybersecurity companies improve their services, it's also helping cyber criminals and state-sponsored cyberthreats become more sophisticated, efficient, and difficult to detect. The company is innovating quickly to address these new threats, and AI should continue to be a major growth driver in the cybersecurity space. With a price-to-sales (P/S) ratio of about 6.4 based on analysts' fiscal 2026 revenue estimates, Okta is still reasonably valued compared to many other leading cybersecurity stocks. As such, this is a good opportunity to pick up some shares while they take a breather from their 2025 rally. Before you buy stock in Okta, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Okta wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Okta. The Motley Fool has a disclosure policy. After a Sharp Rally, Okta Stock Pulls Back on Cautious Outlook -- Time to Buy the Dip? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Jamie Dimon says ‘don't put a good foot forward, put the truth forward' and reveals what would get him into public service
CEO Jamie Dimon was asked about leadership lessons at the end of a wide-ranging interview during the Reagan National Economic Forum on Friday. He talked about getting out, listening to people, observing, providing honest assessments, and having humility. He also explained what would lure him from the private sector to the public sector. Wall Street's longest-tenured CEO said it's better to give an honest assessment than to make the boss feel good. At the end of a wide-ranging interview during the Reagan National Economic Forum on Friday, CNBC's Morgan Brennan asked JPMorgan Chase CEO Jamie Dimon about leadership lessons. The first thing he said was, 'get out, get out, get out, get out, talk to people, talk to clients. I talk to everybody.' Noting that President Dwight Eisenhower, a Republican, regularly met with Democratic leaders, Dimon also discussed the importance of hearing opposing views as well as listening to complaints and learning about rivals. 'Observe, observe, observe, and have all your people do it,' he added. 'And it's a never-ending process. Because we have competitors from around the world, and they're smart, and they're tough, and they're coming.' Then he turned to what makes companies that were once pace-setters in their respective industries fail. Dimon pointed to arrogance, greed, complacency, and bureaucracy. Companies can 'bull—t' themselves about how they're earning money and why, while executives may feel pressure to make the boss feel good and avoid embarrassing someone, he explained. 'When people say to me, put a good foot forward, I always say, don't put a good foot forward, put the truth forward, 100% the truth,' Dimon said. 'Tell us, and we will deal with it. It's OK. So a deep, honest assessment.' He also put humility and curiosity on the list of traits leaders should have, saying 'people don't want to work for jerks' and don't want to work for bosses who blame others. Meanwhile, CEO succession at the world's biggest bank by market cap has been an ongoing parlor game on Wall Street, and Dimon recently reaffirmed that he is stepping down sometime in the next two to four years. But at the still relatively young age of 69, there has been widespread speculation that he might have a second act in the government, either in elected office or an appointed role. Earlier this year, he even admitted that he considered running for president of the United States, but decided against it because didn't want to spend so much time away from his family. And while running for re-election last summer, Donald Trump suggested he might consider Dimon for Treasury secretary, though he later ruled him out. On Friday, Dimon was asked what it would take for him to enter public service. His answer hinted at some humility. 'Alright, ready? I'll tell you: if I thought I could really win, which I don't think I could,' he said. This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
9 hours ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
